A hand wearing blue gloves holding an orange petri dish with visible black spots, against a plain white background.

About us

OUR MISSION

Revolutionizing autoimmune
disease treatment with
innovative biologics

Signal26 Biotherapeutics is dedicated to developing a groundbreaking biologic treatment for Psoriasis. Through our partnership with a leading research university in Switzerland, we have identified the interleukin 26 (IL-26) signalling pathway as a novel target. With our novel anti-IL-26 antibody, we aim to revolutionize the treatment of autoimmune diseases.

Learn more

Contact us

Based on active research supported by leading institutions and partners

WHAT WE DO

Revolutionizing the treatment of autoimmune disorders, one signal at a time

Demonstrated Efficacy

Signal26 Biotherapeutics is a Biotechnology startup dedicated to advancing the development of a novel biological drug for the treatment of Pustular Psoriasis. In collaboration with our colleagues at CHUV, we are pioneering research into the role of interleukin 26 (IL-26) in
autoimmune disorders.

Roadmap

Our team

INNOVATION

Our team

Meet the experienced team behind Signal26 Biotherapeutics

CEO

Julien Grogg, PhD

Dr. Grogg is a Biomedical Engineer by training, holding a PhD in Medical Sciences from Paris-Saclay and an MBA from IMD. A seasoned leader who has co-invented four medical products and navigated the path to market for one, he bridges the gap between deep technical research and scalable corporate strategy.

HEAD OF R&D

Lefteris Zacharia, PhD

Dr. Zacharia is an associate professor of Pharmacology at the University of Nicosia who has been leading the anti-IL-26 project since 2021 as part of AVVA Pharmaceuticals LTD.

Senior Biotechnologist

Mylène Talabardon, PhD

Dr. Talabardon earned her PhD in Biotechnology from the Ohio State University. With over 20 years of experience, she has led pharmaceutical teams in process development, validation, and regulatory strategy, shaping global approaches to biologics manufacturing.

research scientist

Yu-Noël Larpin, PhD

Dr. Yu-Noël Larpin earned his PhD in Cell Biology from the University of Bern. With expertise in molecular biology, biophysics, and entrepreneurial leadership, he combines scientific discovery with innovation to advance therapies for autoinflammatory diseases.

QA SPECIALIST

Victoria De La Mare

Ms. De La Mare brings a strong background in GMP and GDP compliance. As a certified Lead Auditor, she has successfully led and supported both internal and external audits, ensuring adherence to regulatory and quality standards.

ACCOUNTING & ADMINISTRATION SPECIALIST

Ueli Ambauen

Mr. Ambauen has extensive experience in finance and accounting in Switzerland. At Signal26 Biotherapeutics, he has been responsible for accounting and administration.

A scientist wearing blue gloves using a multichannel pipette to transfer liquid into a well plate in a laboratory setting.

OUR TEAM

We are a team of experts
dedicated to bringing relief to
thousands of patients.

Signal26 Biotherapeutics is dedicated to advancing the global understanding of autoinflammation mechanisms and their contribution to Psoriasis, Inflammatory Bowel Disease, and Rheumatoid Arthritis. Through our partnership with a leading research university in Switzerland, we have identified the interleukin 26 (IL-26) signalling pathway as a novel target.

Our novel anti-IL-26 antibody has shown promising results in blocking the aberrant function of IL-26 in murine models. We are committed to swiftly advancing this innovative therapy to clinical trials.

A scientist wearing yellow safety goggles examining an orange liquid in a round-bottom flask, illuminated by bright light.

Interested in joining the team?

We're always looking to connect with inspiring individuals. Browse opportunities and connect with us below.

Careers

About us

Revolutionizing autoimmune
disease treatment with
innovative biologics